Natalia Rodon¹, Ruth Roman¹, Montse Verdu^1,3 ,Miquel Calvo⁴, Beatriz Garcia-Pelaez¹, Marta Gonzalez¹, Carme Pubill³ and Xavier Puig^1,2,3.

¹BIOPAT. Biopatologia Molecular SL, Grup Assistència. ²Hospital de Barcelona-SCIAS, Grup Assistencia. ³Histopat Laboratoris. ⁴Departament d’Estadística, Facultat de Biologia. UB. Barcelona.

KRAS oncogenic mutations, present in approximately 30-50% of colorectal carcinomas (CRC), result in a lack of response to EGFR inhibitors. The aim of this study was to confirm with a multivariate analysis the correlations observed in our initial univariate approach between KRAS mutational status and […]

M Verdu^1,3, R Roman¹, M Calvo⁴, N Rodon¹, B Garcia¹, M Gonzalez¹ and X Puig^1,2,3.

¹BIOPAT.Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain; ²Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona, Spain; ³Histopat Laboratoris, Barcelona, Spain and ⁴Statistics Department, Universitat Barcelona, Barcelona, Spain.

Background: Micropapillary carcinoma (MC) is accepted as an aggressive variant of colorectal adenocarcinoma, described for the first time in the breast and later in other organs. At present, there are a limited number of colorectal MC series reported, not enough to define […]